223 related articles for article (PubMed ID: 24381243)
21. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.
Montgomery SA; Mansuy L; Ruth AC; Li D; Gommoll C
Int Clin Psychopharmacol; 2014 Jan; 29(1):26-35. PubMed ID: 24172160
[TBL] [Abstract][Full Text] [Related]
22. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
[TBL] [Abstract][Full Text] [Related]
23. Milnacipran for fibromyalgia.
Dempsey J
Issues Emerg Health Technol; 2008 Feb; (114):1-4. PubMed ID: 18354855
[TBL] [Abstract][Full Text] [Related]
24. Levomilnacipran (Fetzima) for Major Depressive Disorder.
Zaman S; McLaughlin MR
Am Fam Physician; 2015 Oct; 92(8):727-31. PubMed ID: 26554414
[No Abstract] [Full Text] [Related]
25. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
26. Effect of co-administration of a serotonin-noradrenaline reuptake inhibitor and a dopamine agonist on extracellular monoamine concentrations in rats.
Kitaichi Y; Inoue T; Izumi T; Nakagawa S; Tanaka T; Masui T; Koyama T
Eur J Pharmacol; 2008 Apr; 584(2-3):285-90. PubMed ID: 18336812
[TBL] [Abstract][Full Text] [Related]
27. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
28. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials.
Blier P; Gommoll C; Chen C; Kramer K
J Affect Disord; 2017 Mar; 210():273-279. PubMed ID: 28068615
[TBL] [Abstract][Full Text] [Related]
29. The effectiveness of lithium augmentation of milnacipran: preliminary data using the modified Japanese Psychopharmacology Algorithm.
Kobayashi N; Sawamura T; Yoshida T; Yoshino A; Nomura S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):279-81. PubMed ID: 15658504
[TBL] [Abstract][Full Text] [Related]
30. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
31. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
Palmer EC; Binns LN; Carey H
Ann Pharmacother; 2014 Aug; 48(8):1030-1039. PubMed ID: 24811398
[TBL] [Abstract][Full Text] [Related]
32. Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study.
Wesnes KA; Gommoll C; Chen C; Sambunaris A; McIntyre RS; Harvey PD
Int Clin Psychopharmacol; 2017 Mar; 32(2):72-79. PubMed ID: 27861191
[TBL] [Abstract][Full Text] [Related]
33. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
Leo RJ; Brooks VL
Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
[TBL] [Abstract][Full Text] [Related]
34. Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants.
Chen L; Boinpally R; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
Clin Drug Investig; 2014 May; 34(5):351-9. PubMed ID: 24677141
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
36. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.
Auclair AL; Martel JC; Assié MB; Bardin L; Heusler P; Cussac D; Marien M; Newman-Tancredi A; O'Connor JA; Depoortère R
Neuropharmacology; 2013 Jul; 70():338-47. PubMed ID: 23499664
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.
Montgomery SA; Gommoll CP; Chen C; Greenberg WM
CNS Spectr; 2015 Apr; 20(2):148-56. PubMed ID: 24902007
[TBL] [Abstract][Full Text] [Related]
38. LEVOMILNACIPRAN--A SUCCESSOR OF MILNACIPRAN WITH A HIGHER NORADRENERGIC SELECTIVITY.
Zadka Ł; Dziwota E; Olajossy M
Acta Pol Pharm; 2016; 73(2):285-9. PubMed ID: 27180420
[TBL] [Abstract][Full Text] [Related]
39. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.
Tignol J; Pujol-Domenech J; Chartres JP; Léger JM; Plétan Y; Tonelli I; Tournoux A; Pezous N
Acta Psychiatr Scand; 1998 Feb; 97(2):157-65. PubMed ID: 9517912
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
Chen L; Boinpally R; Gad N; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
